quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 25, 2026

Qualcomm Is Down 24% in 2026 and Just Announced a $20 Billion Buyback. Is That Bullish or a Warning Sign?

View original at nasdaq.com
“Long-term debt is manageable at $14.8 billion, and Qualcomm has generated $12.9 billion in trailing free cash flow.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Qualcomm can afford both the buyback and dividend as it has a solid balance sheet with $7.2 billion in cash and $12.9 billion in trailing free cash flow

    60% confidence
  • The Motley Fool Stock Advisor analyst team identified 10 best stocks for investors to buy now and Qualcomm wasn't one of them

    60% confidence
  • Qualcomm's partnership with Apple could end this year, as Apple is developing its own custom-designed modem chips

    60% confidence
  • The buyback may be undervalued at the moment, but I'd personally hold off on investing until seeing more progress in automotive and IoT revenue

    60% confidence
  • Qualcomm's partnership with Apple could end this year, as Apple is developing its own custom-designed modem chips

    60% confidence
  • Qualcomm was not one of the 10 best stocks for investors to buy now

    60% confidence
  • Qualcomm may be undervalued at the moment

    60% confidence
  • I'd personally hold off on investing for now, at least until seeing more progress in automotive and IoT revenue

    60% confidence
  • Stock Advisor's total average return is 913% compared to 185% for the S&P 500

    60% confidence
  • Qualcomm looks cheap right now, trading at 12 times forward earnings

    60% confidence
  • Would personally hold off on investing in Qualcomm for now, at least until seeing more progress in automotive and IoT revenue

    60% confidence
  • The memory shortage is impacting Qualcomm's smartphone component sales

    60% confidence
  • Qualcomm's partnership with Apple could end this year as Apple develops its own custom-designed modem chips

    60% confidence
  • Stock Advisor's total average return is 913%, a market-crushing outperformance compared to 185% for the S&P 500

    60% confidence
  • The memory shortage is impacting Qualcomm's smartphone component sales, which is its core business

    60% confidence
  • The memory shortage is impacting Qualcomm's smartphone component sales, which is its core business

    60% confidence
  • Qualcomm may be undervalued at the moment

    60% confidence
  • The 10 best stocks for investors to buy now do not include Qualcomm

    60% confidence

Data points we hold from this source

Qualcomm Incorporated · forward pe ratio12 ratio
Qualcomm Incorporated · quarterly dividend0.92 USD
Qualcomm Incorporated · stock return11 percent
Qualcomm Incorporated · total return229 percent
Qualcomm Incorporated · pe ratio forward12 ratio
Qualcomm Incorporated · free cash flow12.9 USD
Qualcomm Incorporated · dividend quarterly0.89 USD
Qualcomm Incorporated · free cash flow12.9 USD
Qualcomm Incorporated · quarterly dividend0.89 USD
Qualcomm Incorporated · debt14.8 USD
Qualcomm Incorporated · cash7.2 USD
Qualcomm Incorporated · iot revenue1.7 USD
Qualcomm Incorporated · automotive revenue1.1 USD
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com